- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 239/84 - Atomes d'azote
Détention brevets de la classe C07D 239/84
Brevets de cette classe: 295
Historique des publications depuis 10 ans
|
11
|
25
|
18
|
15
|
21
|
20
|
22
|
24
|
18
|
7
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Aic246 AG & Co. KG | 31 |
17 |
| Neupharma, Inc. | 71 |
13 |
| Cornell University | 3348 |
11 |
| ArQule, Inc. | 136 |
9 |
| Blueprint Medicines Corporation | 239 |
8 |
| Gilead Sciences, Inc. | 2070 |
8 |
| HMI Medical Innovations, LLC | 14 |
8 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2895 |
7 |
| Merck Patent GmbH | 5756 |
6 |
| Araxes Pharma LLC | 92 |
6 |
| Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. | 13 |
6 |
| Eisai R&D Management Co., Ltd. | 1210 |
6 |
| Abbisko Therapeutics Co., Ltd. | 113 |
6 |
| Merck Sharp & Dohme LLC | 3734 |
5 |
| Bristol-myers Squibb Company | 4848 |
4 |
| The Regents of the University of California | 20230 |
4 |
| Merck Sharp & Dohme Corp. | 2190 |
4 |
| Pfizer Inc. | 3397 |
4 |
| Convergene LLC | 11 |
4 |
| Deciphera Pharmaceuticals, LLC | 227 |
4 |
| Autres propriétaires | 155 |